Contemporary approaches to in-transit melanoma

Jennifer A. Perone, Nellie Farrow, Douglas Tyler, Georgia M. Beasley

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.

Original languageEnglish (US)
Pages (from-to)292-300
Number of pages9
JournalJournal of Oncology Practice
Volume14
Issue number5
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Melanoma
Oncolytic Viruses
Drug Therapy
Therapeutics
Injections
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Contemporary approaches to in-transit melanoma. / Perone, Jennifer A.; Farrow, Nellie; Tyler, Douglas; Beasley, Georgia M.

In: Journal of Oncology Practice, Vol. 14, No. 5, 01.05.2018, p. 292-300.

Research output: Contribution to journalReview article

Perone, Jennifer A. ; Farrow, Nellie ; Tyler, Douglas ; Beasley, Georgia M. / Contemporary approaches to in-transit melanoma. In: Journal of Oncology Practice. 2018 ; Vol. 14, No. 5. pp. 292-300.
@article{462b06786a2a4be5b52f2dbb7bbb5664,
title = "Contemporary approaches to in-transit melanoma",
abstract = "In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.",
author = "Perone, {Jennifer A.} and Nellie Farrow and Douglas Tyler and Beasley, {Georgia M.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1200/JOP.18.00063",
language = "English (US)",
volume = "14",
pages = "292--300",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Contemporary approaches to in-transit melanoma

AU - Perone, Jennifer A.

AU - Farrow, Nellie

AU - Tyler, Douglas

AU - Beasley, Georgia M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.

AB - In-transit melanoma represents a distinct disease pattern of heterogeneous superficial tumors. Many treatments have been developed specifically for this type of disease, including regional chemotherapy and a variety of directly injectable agents. Novel strategies include the intralesional delivery of oncolytic viruses and immunocytokines. The combination of intralesional or regional chemotherapy with systemic immune checkpoint inhibitors also is a promising approach. In the current review, we examine the general management of the workup of patients with in-transit disease, the range of available therapies, and recommendations for specific therapies for an individual patient.

UR - http://www.scopus.com/inward/record.url?scp=85061229716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061229716&partnerID=8YFLogxK

U2 - 10.1200/JOP.18.00063

DO - 10.1200/JOP.18.00063

M3 - Review article

C2 - 29746804

AN - SCOPUS:85061229716

VL - 14

SP - 292

EP - 300

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 5

ER -